Last reviewed · How we verify
LM-108 in combination with Toripalimab
LM-108 combined with Toripalimab works by blocking immune checkpoints to enhance anti-tumor immunity, with LM-108 targeting a specific immune pathway while Toripalimab blocks PD-1.
LM-108 combined with Toripalimab works by blocking immune checkpoints to enhance anti-tumor immunity, with LM-108 targeting a specific immune pathway while Toripalimab blocks PD-1. Used for Solid tumors (specific indications under investigation in Phase 3).
At a glance
| Generic name | LM-108 in combination with Toripalimab |
|---|---|
| Sponsor | LaNova Medicines Limited |
| Drug class | Immunotherapy combination (checkpoint inhibitor + unknown immunomodulator) |
| Target | PD-1 (Toripalimab); LM-108 target unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Toripalimab is a PD-1 inhibitor that releases the brakes on T-cell mediated anti-tumor immunity. LM-108's specific mechanism is not publicly detailed, but the combination is designed to provide complementary immunomodulation. This dual approach aims to overcome resistance to single-agent checkpoint inhibition in solid tumors.
Approved indications
- Solid tumors (specific indications under investigation in Phase 3)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (PHASE3)
- A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours (PHASE2)
- LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: